Given the benefits of organ protection and long-term health outcomes, SGLT2 inhibitors have now emerged as class I recommendations in the guidelines for treatment of cardiac and renal disease irrespective of diabetes status [132,133]. Here, SLC5A2 is linked to diabetes mellitus.